Y3L: EQ-5D-Y-3L value set data

In fragla/eq5d: Methods for Analysing 'EQ-5D' Data and Calculating 'EQ-5D' Index Scores

EQ-5D-Y-3L value set data

Description

EQ-5D-Y-3L value set calculation data for Belgium, Brazil, China, Germany, Hungary, Indonesia, Japan, Netherlands, Slovenia and Spain.

Usage

Y3L

Format

An object of class data.frame with 14 rows and 10 columns.

Source

• Belgium: Dewilde S, Roudijk B, Tollenaar NH, Ramos-Goñi JM. An EQ-5D-Y-3L Value Set for Belgium. Pharmacoeconomics. 2022 Nov 1:1–12. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1007/s40273-022-01187-x")}. Epub ahead of print. PMID: 36316544.

• Brazil: Espirito Santo CM, Miyamoto GC, Santos VS, Ben ÂJ, Finch AP, Roudijk B, de Jesus-Moraleida FR, Stein AT, Santos M, Yamato TP. Estimating an EQ-5D-Y-3L Value Set for Brazil. Pharmacoeconomics. 2024 Jul 2. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1007/s40273-024-01404-9")}. Epub ahead of print. PMID: 38954389.

• China: Yang Z, Jiang J, Wang P, Jin X, Wu J, Fang Y, Feng D, Xi X, Li S, Jing M, Zheng B, Huang W, Luo N. Estimating an EQ-5D-Y-3L Value Set for China. Pharmacoeconomics. 2022 Nov 18. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1007/s40273-022-01216-9")}. Epub ahead of print. PMID: 36396878.

• Germany: Kreimeier S, Mott D, Ludwig K, Greiner W; IMPACT HTA HRQoL Group. EQ-5D-Y Value Set for Germany. Pharmacoeconomics. 2022 May 23:1–13. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1007/s40273-022-01143-9")}. Epub ahead of print. PMID: 35604633.

• Hungary: Rencz F, Ruzsa G, Bató A, Yang Z, Finch AP, Brodszky V. Value Set for the EQ-5D-Y-3L in Hungary. Pharmacoeconomics. 2022 Sep 20:1–11. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1007/s40273-022-01190-2")}. Epub ahead of print. PMID: 36123448.

• Indonesia: Fitriana TS, Roudijk B, Purba FD, Busschbach JJV, Stolk E. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values. Pharmacoeconomics. 2022 Nov 9. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1007/s40273-022-01210-1")}. Epub ahead of print. PMID: 36348155.

• Japan: Shiroiwa T, Ikeda S, Noto S, Fukuda T, Stolk E. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan. Med Decis Making. 2021 Mar 23:272989X211001859. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1177/0272989X211001859")}. Epub ahead of print. PMID: 33754886.

• Netherlands:Roudijk B, Sajjad A, Essers B, Lipman S, Stalmeier P, Finch AP. A Value Set for the EQ-5D-Y-3L in the Netherlands. Pharmacoeconomics. 2022 Oct 10:1–11. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1007/s40273-022-01192-0")}. Epub ahead of print. PMID: 36216977.

• Slovenia: Prevolnik Rupel V, Ogorevc M; IMPACT HTA HRQoL Group. EQ-5D-Y Value Set for Slovenia. Pharmacoeconomics. 2021 Feb 10. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1007/s40273-020-00994-4")}. Epub ahead of print. PMID: 33565048.

• Spain: Ramos-Goñi JM, Oppe M, Estévez-Carrillo A, Rivero-Arias O; IMPACT HTA HRQoL Group. Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data. Value Health. 2022 May;25(5):835-843. \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1016/j.jval.2021.10.013")}. Epub 2021 Dec 6. PMID: 35500952..

fragla/eq5d documentation built on Nov. 27, 2024, 3:23 a.m.